annual EBITDA:
-$13.72M-$5.46M(-65.99%)Summary
- As of today (June 29, 2025), AKBA annual EBITDA is -$13.72 million, with the most recent change of -$5.46 million (-65.99%) on December 31, 2024.
- During the last 3 years, AKBA annual EBITDA has risen by +$212.81 million (+93.94%).
- AKBA annual EBITDA is now -65.99% below its all-time high of -$8.27 million, reached on December 31, 2023.
Performance
AKBA EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
$14.20M+$20.78M(+315.68%)Summary
- As of today (June 29, 2025), AKBA quarterly EBITDA is $14.20 million, with the most recent change of +$20.78 million (+315.68%) on March 31, 2025.
- Over the past year, AKBA quarterly EBITDA has increased by +$20.31 million (+332.26%).
- AKBA quarterly EBITDA is now -67.67% below its all-time high of $43.91 million, reached on June 30, 2022.
Performance
AKBA quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
$6.59M+$20.31M(+148.01%)Summary
- As of today (June 29, 2025), AKBA TTM EBITDA is $6.59 million, with the most recent change of +$20.31 million (+148.01%) on March 31, 2025.
- Over the past year, AKBA TTM EBITDA has increased by +$5.06 million (+330.80%).
- AKBA TTM EBITDA is now at all-time high.
Performance
AKBA TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
AKBA EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -66.0% | +332.3% | +330.8% |
| 3 y3 years | +93.9% | +129.6% | +103.0% |
| 5 y5 years | +94.5% | +128.9% | +102.9% |
AKBA EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -66.0% | +93.9% | -67.7% | +129.6% | at high | +103.0% |
| 5 y | 5-year | -66.0% | +96.0% | -67.7% | +108.7% | at high | +101.9% |
| alltime | all time | -66.0% | +96.0% | -67.7% | +108.7% | at high | +101.9% |
AKBA EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | $14.20M(-315.7%) | $6.59M(-148.0%) |
| Dec 2024 | -$13.72M(+66.0%) | -$6.58M(+64.4%) | -$13.72M(-419.3%) |
| Sep 2024 | - | -$4.00M(-234.5%) | $4.30M(-7.2%) |
| Jun 2024 | - | $2.98M(-148.7%) | $4.63M(+202.7%) |
| Mar 2024 | - | -$6.11M(-153.4%) | $1.53M(-118.5%) |
| Dec 2023 | -$8.27M(-79.8%) | $11.44M(-411.4%) | -$8.27M(-43.8%) |
| Sep 2023 | - | -$3.67M(+2885.4%) | -$14.72M(-71.6%) |
| Jun 2023 | - | -$123.00K(-99.2%) | -$51.77M(+569.7%) |
| Mar 2023 | - | -$15.91M(-419.1%) | -$7.73M(-80.6%) |
| Dec 2022 | -$40.84M(-82.0%) | $4.98M(-112.2%) | -$39.76M(-61.2%) |
| Sep 2022 | - | -$40.72M(-192.7%) | -$102.48M(-4.0%) |
| Jun 2022 | - | $43.91M(-191.6%) | -$106.73M(-51.3%) |
| Mar 2022 | - | -$47.93M(-17.0%) | -$219.21M(-3.2%) |
| Dec 2021 | -$226.53M(-34.0%) | -$57.74M(+28.4%) | -$226.53M(-8.6%) |
| Sep 2021 | - | -$44.98M(-34.4%) | -$247.89M(-2.4%) |
| Jun 2021 | - | -$68.57M(+24.1%) | -$253.98M(-27.3%) |
| Mar 2021 | - | -$55.25M(-30.1%) | -$349.24M(+1.8%) |
| Dec 2020 | -$343.13M(+38.6%) | -$79.10M(+54.9%) | -$343.13M(-1.7%) |
| Sep 2020 | - | -$51.06M(-68.8%) | -$349.24M(+1.4%) |
| Jun 2020 | - | -$163.82M(+233.3%) | -$344.35M(+49.5%) |
| Mar 2020 | - | -$49.15M(-42.3%) | -$230.36M(-7.0%) |
| Dec 2019 | -$247.64M(+40.9%) | -$85.20M(+84.5%) | -$247.64M(-1.3%) |
| Sep 2019 | - | -$46.17M(-7.4%) | -$250.81M(+8.0%) |
| Jun 2019 | - | -$49.84M(-25.0%) | -$232.26M(+6.6%) |
| Mar 2019 | - | -$66.43M(-24.8%) | -$217.87M(+24.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | -$175.74M(+131.1%) | -$88.38M(+220.0%) | -$175.74M(+142.2%) |
| Sep 2018 | - | -$27.62M(-22.1%) | -$72.56M(+5.2%) |
| Jun 2018 | - | -$35.45M(+45.9%) | -$68.95M(+24.2%) |
| Mar 2018 | - | -$24.30M(-264.1%) | -$55.52M(-27.0%) |
| Dec 2017 | -$76.06M(-44.1%) | $14.81M(-161.7%) | -$76.06M(-40.9%) |
| Sep 2017 | - | -$24.01M(+9.0%) | -$128.78M(-8.6%) |
| Jun 2017 | - | -$22.02M(-50.9%) | -$140.86M(-9.1%) |
| Mar 2017 | - | -$44.84M(+18.2%) | -$154.99M(+13.8%) |
| Dec 2016 | -$136.16M(+121.7%) | -$37.92M(+5.1%) | -$136.16M(+15.1%) |
| Sep 2016 | - | -$36.09M(-0.1%) | -$118.28M(+16.1%) |
| Jun 2016 | - | -$36.14M(+38.9%) | -$101.84M(+33.0%) |
| Mar 2016 | - | -$26.01M(+29.8%) | -$76.55M(+24.6%) |
| Dec 2015 | -$61.42M(+62.1%) | -$20.04M(+2.0%) | -$61.42M(+18.2%) |
| Sep 2015 | - | -$19.64M(+80.9%) | -$51.97M(+24.0%) |
| Jun 2015 | - | -$10.86M(-0.2%) | -$41.90M(+7.8%) |
| Mar 2015 | - | -$10.88M(+2.7%) | -$38.87M(+2.6%) |
| Dec 2014 | -$37.89M(+137.8%) | -$10.59M(+10.7%) | -$37.89M(+13.1%) |
| Sep 2014 | - | -$9.57M(+22.3%) | -$33.50M(+19.8%) |
| Jun 2014 | - | -$7.83M(-20.9%) | -$27.96M(+20.2%) |
| Mar 2014 | - | -$9.90M(+59.7%) | -$23.26M(+46.0%) |
| Dec 2013 | -$15.93M(+86.9%) | -$6.20M(+53.7%) | -$15.93M(+63.7%) |
| Sep 2013 | - | -$4.03M(+29.3%) | -$9.73M(+70.8%) |
| Jun 2013 | - | -$3.12M(+21.1%) | -$5.70M(+121.1%) |
| Mar 2013 | - | -$2.58M | -$2.58M |
| Dec 2012 | -$8.52M | - | - |
FAQ
- What is Akebia Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Akebia Therapeutics?
- What is Akebia Therapeutics annual EBITDA year-on-year change?
- What is Akebia Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Akebia Therapeutics?
- What is Akebia Therapeutics quarterly EBITDA year-on-year change?
- What is Akebia Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Akebia Therapeutics?
- What is Akebia Therapeutics TTM EBITDA year-on-year change?
What is Akebia Therapeutics annual EBITDA?
The current annual EBITDA of AKBA is -$13.72M
What is the all time high annual EBITDA for Akebia Therapeutics?
Akebia Therapeutics all-time high annual EBITDA is -$8.27M
What is Akebia Therapeutics annual EBITDA year-on-year change?
Over the past year, AKBA annual EBITDA has changed by -$5.46M (-65.99%)
What is Akebia Therapeutics quarterly EBITDA?
The current quarterly EBITDA of AKBA is $14.20M
What is the all time high quarterly EBITDA for Akebia Therapeutics?
Akebia Therapeutics all-time high quarterly EBITDA is $43.91M
What is Akebia Therapeutics quarterly EBITDA year-on-year change?
Over the past year, AKBA quarterly EBITDA has changed by +$20.31M (+332.26%)
What is Akebia Therapeutics TTM EBITDA?
The current TTM EBITDA of AKBA is $6.59M
What is the all time high TTM EBITDA for Akebia Therapeutics?
Akebia Therapeutics all-time high TTM EBITDA is $6.59M
What is Akebia Therapeutics TTM EBITDA year-on-year change?
Over the past year, AKBA TTM EBITDA has changed by +$5.06M (+330.80%)